Current status of maintenance therapy for advanced ovarian cancer

od Hope, Joanie Mayer, Blank, Stephanie V
Izdano 2010

Coronavirus concerns: What do women with gynecologic cancer need to know during the COVID-19 crisis?

od Frey, Melissa K., Blank, Stephanie V.
Izdano u Gynecol Oncol (2020)

Occult tubal carcinoma found at risk reducing salpingectomy in a BRCA1 carrier()

od Kim, Sarah H., Frey, Melissa K., Blank, Stephanie V.
Izdano 2014

Breast cancer in the setting of fertility-sparing treatment for endometrial cancer

od Moss, Haley A., Frey, Melissa K., Blank, Stephanie V.
Izdano u Gynecol Oncol Rep (2014)

Primary breast cancer of the vulva with concurrent breast and endometrial cancers: A case report and literature review

od Li, Sue, Schwartz, Melissa, Everest, Sedef, Blank, Stephanie V.
Izdano u Gynecol Oncol Rep (2018)

“Best practices in risk reducing bilateral salpingo-oophorectomy: the influence of surgical specialty”

od Malacarne, Dominique R., Boyd, Leslie R., Long, Yang, Blank, Stephanie V.
Izdano u World J Surg Oncol (2017)

Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer

od Korets, Sharmilee Bansal, Musa, Fernanda, Curtin, John, Blank, Stephanie V., Schneider, Robert J.
Izdano u Gynecol Oncol (2013)

The influence of BRCA variants of unknown significance on cancer risk management decision-making

od Chern, Jing-Yi, Lee, Sarah S., Frey, Melissa K., Lee, Jessica, Blank, Stephanie V.
Izdano u J Gynecol Oncol (2019)

Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer

od Aghajanian, Carol, Goff, Barbara, Nycum, Lawrence R., Wang, Yan V., Husain, Amreen, Blank, Stephanie V.
Izdano u Gynecol Oncol (2015)

Dual mTORC1/2 inhibition as a novel strategy for the re-sensitization and treatment of platinum-resistant ovarian cancer

od Musa, Fernanda, Alard, Amandine, David-West, Gizelka, Curtin, John P., Blank, Stephanie V., Schneider, Robert J.
Izdano u Mol Cancer Ther (2016)

Estrogen and Progesterone Regulate p27kip1 Levels via the Ubiquitin-Proteasome System: Pathogenic and Therapeutic Implications for Endometrial Cancer

od Huang, Kuang-Tzu, Pavlides, Savvas C., Lecanda, Jon, Blank, Stephanie V., Mittal, Khushbakhat R., Gold, Leslie I.
Izdano 2012

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment

od Blank, Stephanie V., Christos, Paul, Curtin, John P., Goldman, Noah, Runowicz, Carolyn D., Sparano, Joseph A., Liebes, Leonard, Chen, Helen X., Muggia, Franco M.
Izdano 2010

OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian,...

od Aghajanian, Carol, Blank, Stephanie V., Goff, Barbara A., Judson, Patricia L., Teneriello, Michael G., Husain, Amreen, Sovak, Mika A., Yi, Jing, Nycum, Lawrence R.
Izdano 2012

Inhibitors of SCF-Skp2/Cks1 E3 Ligase Block Estrogen-Induced Growth Stimulation and Degradation of Nuclear p27(kip1): Therapeutic Potential for Endometrial Cancer

od Pavlides, Savvas C., Huang, Kuang-Tzu, Reid, Dylan A., Wu, Lily, Blank, Stephanie V., Mittal, Khushbakhat, Guo, Lankai, Rothenberg, Eli, Rueda, Bo, Cardozo, Timothy, Gold, Leslie I.
Izdano 2013

A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan for Patients with Previously Treated Ovarian Cancer

od Stein, Stacey M., Tiersten, Amy, Hochster, Howard S., Blank, Stephanie V., Pothuri, Bhavana, Curtin, John, Shapira, Ilan, Levinson, Benjamin, Ivy, Percy, Joseph, Benson, Guddati, Achuta K., Muggia, Franco
Izdano 2013

Impact of the coronavirus disease 2019 pandemic on the quality of life for women with ovarian cancer

od Frey, Melissa K., Ellis, Annie E., Zeligs, Kristen, Chapman-Davis, Eloise, Thomas, Charlene, Christos, Paul J., Kolev, Valentin, Prasad-Hayes, Monica, Cohen, Samantha, Holcomb, Kevin, Blank, Stephanie V.
Izdano u Am J Obstet Gynecol (2020)

Phase I and Pharmacokinetic Study of Veliparib, a PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Triple Negative Breast Cancer with L...

od Pothuri, Bhavana, Brodsky, Allison L, Sparano, Joseph A, Blank, Stephanie V, Kim, Mimi, Hershman, Dawn L, Tiersten, Amy, Kiesel, Brian F, Beumer, Jan H, Liebes, Leonard, Muggia, Franco
Izdano u Cancer Chemother Pharmacol (2020)

Shared immunogenic poly-epitope frameshift mutations in microsatellite unstable tumors

od Roudko, Vladimir, Bozkus, Cansu Cimen, Orfanelli, Theofano, McClain, Christopher B., Carr, Caitlin, O’Donnell, Timothy, Chakraborty, Lauren, Samstein, Robert, Huang, Kuan-lin, Blank, Stephanie V., Greenbaum, Benjamin, Bhardwaj, Nina
Izdano u Cell (2020)

Adapting and avoiding coping strategies for women with ovarian cancer during the COVID-19 pandemic

od Frey, Melissa K., Chapman-Davis, Eloise, Glynn, Shannon M., Lin, Jenny, Ellis, Annie E., Tomita, Shannon, Fowlkes, Rana Khan, Thomas, Charlene, Christos, Paul J., Cantillo, Evelyn, Zeligs, Kristen, Holcomb, Kevin, Blank, Stephanie V.
Izdano u Gynecol Oncol (2021)

Paclitaxel Plus Oxaliplatin for Recurrent or Metastatic Cervical Cancer: A New York Cancer Consortium Study

od Kuo, Dennis Yi-Shin, Blank, Stephanie V., Christo, Paul J., Kim, Mimi, Caputo, Thomas A., Pothuri, Bhavana, Hershman, Dawn, Goldman, Noah, Ivy, Percy S., Runowicz, Carolyn D., Muggia, Franco, Goldberg, Gary L., Einstein, Mark H.
Izdano 2009